Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal AntibodiesJimson W. D’Souza, Matthew K. Robinson|PLoS ONE|2014Cited by 11